UC Davis Comprehensive Cancer Center | Strategic Alliance Partners

A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.

R. Lor Randall, MD, FACS, discusses the potential symptoms and presentation of mesenchymal chondrosarcoma, as well as highlighted recent case studies that he consulted on for patients with mesenchymal chondrosarcoma.

A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.

A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.

R. Lor Randall, MD, FACS, discusses, the importance of correctly diagnosing mesenchymal chondrosarcoma.

R. Lor Randall, MD, FACS, discusses the presentation and diagnosis of mesenchymal chondrosarcomas, the role of HEY1-NCoA2 gene fusions in the disease, and potential treatment options for this rare subgroup of patients.

R. Lor Randall, MD, FACS, discusses how sarcoma experts from around the world connected to collaborate on the ISKS, the importance of identifying and better understanding sarcoma subgroups, and how these findings could inform prescreening for those at risk for the disease.

New UC Davis study finds relationship between tumor microbiome and immune system in patients with soft tissue sarcoma.

Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.

R. Lor Randall, MD, FACS, discusses the outcomes of combining surgery and pexidartinib in patients with tenosynovial giant cell tumors, what investigators still need to learn about sequencing the CSF1R inhibitor around surgery, and what the combination approach could mean for patients with TGCT.

Robert Lawrence Randall, MD, FACS, discussed the role of biological reconstructions as well as factors that determine whether a patient would benefit more from the reconstructions or traditional prosthetics known as endoprosthetics.

R. Lor Randall, MD, FACS, discusses the significance of addition of surgery to radiation therapy led to improved local control compared with radiation therapy alone in patients with localized pelvic Ewing Sarcoma.

Uproleselan, an agent that disrupts the interaction between leukemia cells and their protective E-selectin microenvironment, is a promising novel AML therapy that may increase the efficacy and durability of other AML treatments.

Center will serve as a hub for commercialization of promising cancer therapies.

Nicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.

R. Lor Randall, MD, FACS, discusses the poor prognosis associated with recurrent pulmonary osteosarcoma, the data from the AOST1421 trial of dinutuxumab plus granulocyte-macrophage colony-stimulating factor, and the need for expanded treatment options in osteosarcoma.

R. Lor Randall, MD, FACS, discusses the findings from a subset analysis of the PARITY trial on the timing of neoadjuvant chemotherapy in patients with lower-extremity sarcomas.

UC Davis cancer researchers hope new technology will help diagnose and treat melanoma more successfully.

R. Lor Randall, MD, FACS, shares the successes achieved so far with machine learning in histopathology, explained the positive effect this technology can have on institutions, and advocated for further use of technology to aid treatment advances.

For patients with osteosarcoma or Ewing sarcoma who develop pathologic fractures, the prognosis remains poor; however, there is still the possibility for limb salvage therapy.

R. Lor Randall, MD, discusses takeaways from the American Academy of Orthopaedic Surgeons 2022 Annual Meeting.

R. Lor Randall, MD, speaks to the findings from a report that said multiple sex-related, racial/ethnic, and socioeconomic status disparities are associated with an increased incidence of metastatic bone disease originating from cancers in the prostate, renal, colon, lung, and breast.

R. Lor Randall, MD, FACS, discusses methods of preventing early failures with compressive osseointegrative endoprosthetic devices of the femur in bone sarcomas.

The Board of Directors of the International Association for the Study of Lung Cancer is pleased to announce the appointment of Karen L. Kelly, M.D. to the position of Chief Executive Officer, effective Spring 2022.

R. Lor Randall, MD, FACS, elaborates on the results of a study and provided insight into future research directions in Ewing sarcoma

R. Lor Randall, MD, FACS, discusses the evolution of limb salvage technologies in bone sarcomas.

R. Lor Randall, MD, FACS, the 10-year results of a retrospective analysis, potential strategies to mitigate early failures in recipients of compressive osseointegrative endoprosthetic devices, and the need for communication between medical oncologists and orthopedic surgeons to ensure patients on chemotherapy receive optimal care.

R. Lor Randall, MD, FACS, discusses initial considerations when treating patients with desmoid tumors.

The use of risk stratification in children and adolescent and young adult patients with synovial sarcoma is an essential approach to appropriately tailoring local and systemic therapy and avoiding overtreatment.

David R. Gandara, highlights key data regarding the earlier integration of targeted therapy in NSCLC, the growing role of molecular testing with tissue and liquid biopsy, and the importance of incorporating a multidisciplinary approach to patient care in the paradigm.